Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide in autosomal dominant polycystic kidney disease (DIPAK Consortium)
2011-005017-37Phase 3Completed
- Sponsor
- DIPAK Consortium
- Start
- May 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of lanreotide in autosomal dominant polycystic kidney disease (ADPKD), Polycystic liver disease (PLD), sponsored by DIPAK Consortium. Started May 2012; status: completed.
02
Drugs
lanreotide
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)Polycystic liver disease (PLD)
Beyond the preview
Go deeper on 2011-005017-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005017-37.